Glide Pharmaceutical Technologies Ltd - Unquoted

Glide Pharma has developed a needle-free drug delivery technology known as Glide that is able to deliver a drug formulation in a solid, semi-liquid form directly through the skin of a patient. The Glide technology has been shown to have a number of benefits when compared to other delivery mechanisms. In trials on human volunteers, Glide's device was shown to be preferable to injection using a standard needle and syringe.

The value of an investment in Hygea vct plc may go down as well as up, in which case an investor may not get back the amount invested. The share price may not reflect the vct’s net asset value. Hygea vct’s investments include holdings in unquoted companies which are small and which carry an above-average level of risk and whose shares may not be readily marketable. The past performance of Hygea vct is not a guide to the future performance.

The tax reliefs available to certain investors in Hygea vct are dependent on the vct maintaining Inland Revenue approval. If this approval is withdrawn, the vct will lose its status and all tax reliefs are likely to be cancelled. Investors must retain their vct shares for three years to retain the up-front income tax relief. The tax rules and regulations governing VCTs are subject to change. An investment in Hygea vct may not be suitable for all investors. Investors should seek advice from a qualified financial advisor. Larpent Newton does not provide and nothing on this website should be construed as investment or tax advice.

The contents of this website have been issued and approved for the purposes of section 21 of the Financial Services and Markets Act 2000 by Larpent Newton & Co Ltd whose registered office is at Steane Grounds Farm, Steane, Brackley, Northants, NN13 5NP. Larpent Newton & Co Ltd is authorised and regulated by the Financial Conduct Authority.